Cargando…
SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
Background: Anti PD-1 antibody immunotherapies like nivolumab and pembrolizumab are newer agents used in the treatment of melanoma and multiple other types of advanced cancers. Immune-mediated endocrinopathies triggered by these drugs are increasingly reported in literature and encountered by endocr...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553338/ http://dx.doi.org/10.1210/js.2019-SUN-173 |